The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma

[1]  Paul A. Northcott,et al.  Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.

[2]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[3]  C. Eberhart,et al.  Medulloblastoma stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Cisneros,et al.  Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease , 2008, Journal of Cell Science.

[5]  D. Ellison,et al.  The origins of medulloblastoma subtypes. , 2008, Annual review of pathology.

[6]  E. Dahl,et al.  Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma , 2007, Oncogene.

[7]  F. Berthold,et al.  Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF‐dependent transcription in medulloblastomas , 2007, International journal of cancer.

[8]  Michael D. Cole,et al.  c-Myc Transforms Human Mammary Epithelial Cells through Repression of the Wnt Inhibitors DKK1 and SFRP1 , 2007, Molecular and Cellular Biology.

[9]  A. Madan,et al.  Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. , 2007, Neuro-oncology.

[10]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Poon,et al.  Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors. , 2005, Human pathology.

[12]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Dawid,et al.  Dishevelled and Wnt signaling: is the nucleus the final frontier? , 2005, Journal of biology.

[14]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[15]  Heather L. Miller,et al.  A molecular fingerprint for medulloblastoma. , 2003, Cancer research.

[16]  P. Kleihues,et al.  AXIN1 mutations but not deletions in cerebellar medulloblastomas , 2003, Oncogene.

[17]  P. Burger,et al.  Nuclear Localization and Mutation of β‐Catenin in Medulloblastomas , 2000 .

[18]  K. Kinzler,et al.  The molecular basis of Turcot's syndrome. , 1995, The New England journal of medicine.

[19]  Andrew P. McMahon,et al.  The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain , 1990, Cell.

[20]  G. Rao.  The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog–Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog–Treated Cerebellar Neural Precursors , 2010 .

[21]  R. Arceci.  An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma , 2009 .

[22]  M. Katoh,et al.  WNT antagonist, SFRP1, is Hedgehog signaling target. , 2006, International journal of molecular medicine.

[23]  P. Burger,et al.  Nuclear localization and mutation of beta-catenin in medulloblastomas. , 2000, Journal of neuropathology and experimental neurology.